Human Biologics Manufacturing in European Union: Market Size, Businesses & Forecast 2026

The human biologics manufacturing industry in the European Union involves the large-scale production of complex, large-molecule medicines derived from living organisms, including therapeutic proteins, monoclonal antibodies, and vaccines. The sector has established a robust international manufacturing footprint, with EU-based companies sourcing approximately 77% of active ingredients for innovative biologic medicines internally as of 2024 (Mabion / European Federation of Pharmaceutical Industries and Associations). Driven by advancements in bioprocessing technologies, an influx of biosimilar entries, and expanding healthcare infrastructure, the industry is transitioning toward digitalized, ag

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Human Biologics Manufacturing in European Union industry cover?

The industry comprises the manufacturing, formulation, and fill-finish processing of biological medical products intended for human use. These complex treatments are produced through biotechnological methods such as recombinant DNA technology, controlled gene expression, and cellular lineage cultivation. The scope spans innovative biological therapies, biosimilars, vaccines, and advanced therapy medicinal products (ATMPs).

• •Covers large-molecule therapeutics including monoclonal antibodies, blood factors, and thrombolytic agents.
• •Includes both proprietary commercial manufacturing and specialized contract development and manufacturing operations (CDMOs).
• •Encompasses upstream processing like cell culture cultivation and downstream purification steps.

Who operates in the industry and how is it structured?

The European market structure features a combination of integrated multinational pharmaceutical corporations maintaining proprietary regional facilities and a specialized layer of Contract Development and Manufacturing Organizations (CDMOs). Industrial operations are densely concentrated within strategic geographic clusters, notably in Ireland, Germany, France, and the Netherlands. These operators cater to both internal European demands and export markets, utilizing automated single-use and stainless-steel bioreactor architectures.

• •Multinational operators run massive internal manufacturing facilities optimized for high-volume commercial supply.
• •Independent and captive CDMOs provide flexible mammalian and microbial fermentation lines to mid-sized biotech firms.
• •Supply chains maintain high localized autonomy, sourcing a substantial majority of biological active pharmaceutical ingredients (APIs) within the EU.

What drives demand in the industry?

Demand is heavily propelled by the rising incidence of chronic oncological, immunological, and metabolic conditions across an aging European demographic. The expiration of foundational patents for primary biologic drugs has simultaneously accelerated the demand for lower-cost biosimilar production pipelines. Furthermore, EU-wide regulatory initiatives and public healthcare frameworks incentivize secure, regionalized manufacturing lines to mitigate drug shortages.

• •Increasing prescription drug spending on biologics, which accounted for approximately €95 billion of EU medicine spending in 2024.
• •Clinical transition toward personalized medicine and advanced targeted therapies requiring specialized micro-lot production.
• •Public health programs and stockpiling requirements for vaccines and critical immunological counter-measures.

Who are the notable companies in the industry?

The competitive environment in the European Union is highly intense, populated by global pharmaceutical giants alongside specialized pure-play contract manufacturers. Companies actively compete on technological sophistication, batch yield efficiencies, and regulatory compliance histories. To maintain market share, operators frequently form strategic alliances and engage in multi-million euro capacity expansions across Member States.

• •Boehringer Ingelheim operates major biopharmaceutical production infrastructure within Germany and Austria.
• •Lonza Group AG maintains extensive European contract manufacturing operations, including significant infrastructure in Visp and Slough.
• •Sanofi SA leverages a deep network of biological manufacturing plants across France and other EU locations.
• •Novo Nordisk A/S continuously expands its European production footprint to support biological and peptide therapeutics.

What are the recent trends and outlook?

The industry is increasingly adopting Industry 4.0 paradigms, integrating continuous bioprocessing, digital twins, and automated quality-control loops to replace traditional batch manufacturing. There is an accelerating regional trend toward scaling up cell and gene therapy manufacturing capabilities to match clinical pipelines. The European Commission is actively supporting this technological evolution with dedicated funding programs under Horizon Europe to modernize biomanufacturing methodologies.

• •Transitioning from traditional stainless-steel installations to flexible, modular single-use bioreactor systems.
• •The European Commission mobilized up to €100 million for microbiome solutions and €250 million for advanced biomanufacturing technologies.
• •Rising integration of artificial intelligence and machine learning to optimize fermentation yields and predict cell culture drift.

How is the industry regulated?

Operations are governed by a stringent, centralized regulatory architecture overseen by the European Medicines Agency (EMA) and national competent authorities. Manufacturers must maintain strict adherence to EudraLex Volume 4 Good Manufacturing Practice (GMP) guidelines covering sterile medicinal products. The operating landscape must continuously adapt to evolving guidance regarding data integrity, environmental biosafety, and validation requirements for advanced therapies.

• •Subject to rigorous pre-approval inspections and strict biological safety batch release testing protocols.
• •The EMA recommended 104 human medicines for marketing authorization in 2025, proving a highly dynamic regulatory pipeline.
• •Compliance involves strict adherence to Annex 1 of the EU GMP guidelines regarding sterile product manufacturing.

Government, statistical and trade sources used for this Claight analysis.

• European Federation of Pharmaceutical Industries and Associations (EFPIA) Annual Report 2025 ·
• European Medicines Agency (EMA) Human Medicines Review 2025 ·
• European Commission Eurostat NACE Rev. 2.1 Framework 2025 ·
• Horizon Europe Work Programmes 2024-2026